NCT05791695View on ClinicalTrials.gov

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

CompletedOBSERVATIONAL
Enrollment

155,413

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

September 15, 2023

Conditions
Intraocular InflammationSuspected Endophthalmitis
Interventions
OTHER

Non Applicable

No study-specific interventions for this observational study.

Trial Locations (1)

10591

Regeneron Research Site, Tarrytown

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT05791695 - A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022 | Biotech Hunter | Biotech Hunter